ArticleMedicine2019
The clinical outcomes for chordomas in the cranial base and spine: A single center experience.
Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Case Report: Anlotinib for advanced chordoma.Frontiers in oncology · 2026Article
- Article
- Ectopic clival craniopharyngioma.Neuroradiology · 2026Article
- Endoscopic Endonasal Resection of Clival Chordomas.Advances and technical standards in neurosurgery · 2025Review
- Surgical management of skull base and spinal chordomas: A case series with comprehensive review of the literature.North American Spine Society journal · 2024Article
- Combined microscopic transoral and endoscopic endonasal approach for a clival chordoma: A case report and literature review.Surgical neurology international · 2024Article
- Metastatic skull base chordoma: A systematic review.Laryngoscope investigative otolaryngology · 2022Review
- Systematic Review Comparing Open versus Endoscopic Surgery in Clival Chordomas and a 10-Year Single-Center Experience.Journal of neurological surgery. Part B, Skull base · 2022Article
- Development and validation of a preoperative MRI-based radiomics nomogram to predict progression-free survival in patients with clival chordomas.Frontiers in oncology · 2022Article
- Metastatic Clivus Chordoma: A Case of a Rare Tumor in a 29-Year-Old African American Male.Cureus · 2022Article
- Prediction of squamous cell carcinoma cases from squamous cell hyperplasia in throat lesions using CT radiomics model.Saudi medical journal · 2021Article
- Outcomes of chordomas of the sacrum and mobile spine: Clinical series with average 6-year follow-up.Journal of craniovertebral junction & spineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to the special growth pattern of chordomas and the limited treatment options currently available, the treatment of chordoma still remains difficult. In this study, we hope to further clarify the relationship between surgical treatment and radiotherapy of chordoma and disease progression.All patients with a primary histopathological diagnosis of clival or spinal chordomas recorded in our institution between 1976 and 2017 were examined.A total of 60 patients (location: skull base/clival, n = 24; vertebral column, n = 5; sacrum, n = 31) had a mean follow-up time of 7.7 years (range 12 months-35 years). Compared with patients who received subtotal resection (n = 5, 5-year and 10-year survival = 61% and 39%, respectively), the annual survival rate of patients who received total resection (n = 55, 5-year and 10-year survival = 67%, respectively) was significantly higher. The overall 10-year survival rate (58%) of patients treated with surgery alone was significantly different from those treated with a combination of surgery and radiation (73%). The long-term prognosis of sacral chordoma was the worst (10-year survival rate = 48%).The best treatment strategy for improved long-term survival in chordoma was a combination of surgical resection and radiation therapy. Adjuvant radiotherapy for chordoma significantly improves disease-free survival, although the long-term survival benefit remains to be determined. A worse prognosis and poor long-term survival are seen in sacral chordomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.